Entering text into the input field will update the search result below

BeiGene's application for tislelizumab accepted in China for liver cancer

Jul. 02, 2020 7:09 AM ETBeiGene, Ltd. (BGNE)BGNEBy: SA News Team
  • The China National Medical Products Administration has accepted BeiGene's (NASDAQ:BGNE) sNDA for anti-PD-1 antibody tislelizumab for the treatment of patients with previously treated unresectable hepatocellular carcinoma, the most common form of liver cancer.
  • Tislelizumab is the first drug from BeiGene’s immuno-oncology biologics program and is being developed internationally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.